Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17441
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilliams, David S-
dc.contributor.authorMouradov, Dmitri-
dc.contributor.authorJorissen, Robert N-
dc.contributor.authorNewman, Marsali R-
dc.contributor.authorAmini, Elham-
dc.contributor.authorNickless, David K-
dc.contributor.authorTeague, Julie A-
dc.contributor.authorFang, Catherine G-
dc.contributor.authorPalmieri, Michelle-
dc.contributor.authorParsons, Marie J-
dc.contributor.authorSakthianandeswaren, Anuratha-
dc.contributor.authorLi, Shan-
dc.contributor.authorWard, Robyn L-
dc.contributor.authorHawkins, Nicholas J-
dc.contributor.authorFaragher, Ian-
dc.contributor.authorJones, Ian T-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorSieber, Oliver M-
dc.date2018-01-30-
dc.date.accessioned2018-04-16T02:10:18Z-
dc.date.available2018-04-16T02:10:18Z-
dc.date.issued2019-03-
dc.identifier.citationGut 2019; 68(3): 465-474-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17441-
dc.description.abstractTumour-infiltrating lymphocyte (TIL) response and deficient DNA mismatch repair (dMMR) are determinants of prognosis in colorectal cancer. Although highly correlated, evidence suggests that these are independent predictors of outcome. However, the prognostic significance of combined TIL/MMR classification and how this compares to the major genomic and transcriptomic subtypes remain unclear. A prospective cohort of 1265 patients with stage II/III cancer was examined for TIL/MMR status and BRAF/KRAS mutations. Consensus molecular subtype (CMS) status was determined for 142 cases. Associations with 5-year disease-free survival (DFS) were evaluated and validated in an independent cohort of 602 patients. Tumours were categorised into four subtypes based on TIL and MMR status: TIL-low/proficient-MMR (pMMR) (61.3% of cases), TIL-high/pMMR (14.8%), TIL-low/dMMR (8.6%) and TIL-high/dMMR (15.2%). Compared with TIL-high/dMMR tumours with the most favourable prognosis, both TIL-low/dMMR (HR=3.53; 95% CI=1.88 to 6.64; Pmultivariate<0.001) and TIL-low/pMMR tumours (HR=2.67; 95% CI=1.47 to 4.84; Pmultivariate=0.001) showed poor DFS. Outcomes of patients with TIL-low/dMMR and TIL-low/pMMR tumours were similar. TIL-high/pMMR tumours showed intermediate survival rates. These findings were validated in an independent cohort. TIL/MMR status was a more significant predictor of prognosis than National Comprehensive Cancer Network high-risk features and was a superior predictor of prognosis compared with genomic (dMMR, pMMR/BRAFwt /KRASwt , pMMR/BRAFmut /KRASwt , pMMR/BRAFwt /KRASmut ) and transcriptomic (CMS 1-4) subtypes. TIL/MMR classification identified subtypes of stage II/III colorectal cancer associated with different outcomes. Although dMMR status is generally considered a marker of good prognosis, we found this to be dependent on the presence of TILs. Prognostication based on TIL/MMR subtypes was superior compared with histopathological, genomic and transcriptomic subtypes.-
dc.language.isoeng-
dc.subjectcolorectal carcinoma-
dc.subjectimmune response-
dc.subjectmolecular pathology-
dc.subjecttumour markers-
dc.titleLymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.-
dc.typeJournal Article-
dc.identifier.journaltitleGut-
dc.identifier.affiliationAustralian Clinical Labs, The Northern Hospital, Epping, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pathology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationSystems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia-
dc.identifier.affiliationClinipath Pathology, Sonic Healthcare, Perth, Western Australia, Australia-
dc.identifier.affiliationOffice of the Deputy Vice-Chancellor (Research), The University of Queensland, Brisbane, Queensland, Australia-
dc.identifier.affiliationFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia-
dc.identifier.affiliationDepartment of Surgery, Western Health, Footscray, Australia-
dc.identifier.affiliationDepartment of Surgery, Royal Melbourne Hospital, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Western Health, Footscray, Victoria, Australia-
dc.identifier.affiliationDepartment of Surgery, The University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationSchool of Biomedical Sciences, Monash University, Clayton, Victoria, Australia-
dc.identifier.doi10.1136/gutjnl-2017-315664-
dc.identifier.pubmedid29382774-
dc.type.austinJournal Article-
local.name.researcherNewman, Marsali R
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptPathology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Nov 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.